Is excessive sugar and refined carbohydrate intake linked to cancer?
March 27, 2026
Hyperinsulinemia—driven by refined carbohydrates and sugar—is linked to obesity, sedentary lifestyle, and type 2 diabetes, all established cancer risk factors.
Modern medicine has achieved remarkable advances in treating cancer. Surgery, radiotherapy, and chemotherapy remain the cornerstones of oncologic care, and for many patients, these interventions are lifesaving. Yet, despite these successes, a troubling reality persists: long‑term success rates for many solid tumors remain low, and the quality of life during and after treatment can be devastating.
Conventional chemotherapy often falls short for solid tumors for several reasons:
The result is a high recurrence rate and significant treatment‑related morbidity. These limitations demand a rethinking—one from eradicating the seed to restoring the soil. In the evolving landscape of oncology, a fundamental question is emerging: Are we focusing too heavily on the "seed" while ignoring the condition of the "soil"? In a compelling new analysis, Dr Salaheldin Halasa and his distinguished co-author Dr Robert Goldman challenge the prevailing genetic-centric view of cancer, proposing a paradigm shift toward understanding the metabolic, hormonal, and immune determinants that govern malignancy. Their work posits a simple yet profound analogy: Hyperinsulinemia is the soil; cancer is the seed. The terrain, not just the seed For decades, the war on cancer has largely been a battle against genetic mutations and clonal evolution. While these factors—the "seed"—are undeniably critical, Drs Halasa and Goldman argue that they do not tell the whole story. Traditional oncology concentrates almost exclusively on eradicating malignant cells after they have emerged—the “seed”—while largely neglecting the host environment that allowed those seeds to take root, evade immune destruction, and thrive. Restoring the body’s metabolic balance—by reversing hyperinsulinemia Hyperinsulinemia, or chronically elevated insulin levels, does not initiate cancer on its own. However, it acts as the biological terrain that prepares the body for malignancy. It creates an environment characterized by sustained growth signaling, metabolic inflexibility, immune dysfunction, angiogenesis, and fibrosis. In this primed soil, oncogene seeds are far more likely to take root, evade immune destruction, and expand. The insight carries implications far beyond oncology. Unlike cancer itself, hyperinsulinemia is detectable early, measurable, and—most importantly—reversible. The authors emphasize that metabolic reprogramming is not a permanent state; it is reversible. Traditional oncology has excelled at eradicating malignant cells after they emerge. While this approach has produced remarkable advances, it often fails to address the host environment that enabled malignancy in the first place. According to Drs Halasa and Goldman, altering the metabolic terrain may be as important as targeting the tumor itself. Interventions that reduce insulin signaling and restore mitochondrial function have demonstrated significant potential. These include:
When these interventions are applied, clinical data suggest a restoration of oxidative metabolism, reactivation of autophagy, improvement in immune surveillance, and subsequent suppression of tumor growth. Perhaps the most actionable insight from this work is the identification of hyperinsulinemia as a powerful, early biomarker. While we often wait for tumors to appear on scans or for genetic markers to manifest, hyperinsulinemia can be detected years before disease onset using existing, cost-effective laboratory tools. The notion that cancer is fundamentally a metabolic disease is not new. In 1931, Dr Otto Warburg received the Nobel Prize for his discovery that cancer cells exhibit a unique form of energy metabolism: they rely on aerobic glycolysis (the breakdown of glucose to lactate) even in the presence of oxygen. Warburg summarized his findings succinctly: “The primary cause of cancer is the replacement of the respiration of oxygen in normal body cells by fermentation of sugar.” In other words, all normal cells are obligate aerobes, while cancer cells behave as partial anaerobes, meeting a large portion of their energy needs through glucose fermentation. Building on Warburg’s work, Dr Thomas Seyfried—author of Cancer as a Metabolic Disease—has advanced the concept that cancer is not primarily driven by mutations but by defects in mitochondrial energy metabolism. From this vantage point, the goal shifts from simply killing cancer cells to restoring normal cellular respiration, thereby depriving malignant cells of their preferred fuel. The central role of hyperinsulinemia If cancer cells are addicted to glucose, then the hormonal environment that governs glucose availability becomes a critical determinant of cancer risk and progression. Hyperinsulinemia—chronically elevated insulin levels—is not cancer itself, but it creates the biological conditions that allow malignancy to flourish. Insulin and insulin‑like growth factor‑1 (IGF‑1) act as potent growth signals, activating the PI3K/Akt/mTOR pathway, which drives proliferation, inhibits apoptosis, and promotes angiogenesis. Moreover, hyperinsulinemia is tightly linked to obesity, sedentary lifestyle, and type 2 diabetes—all established cancer risk factors. Higher circulating C‑peptide, a marker of long‑term insulin secretion has been independently associated with increased cancer risk. Recent studies underscore the clinical relevance. In a study of stage III colon cancer patients, higher dietary glycemic load was associated with increased recurrence and mortality. Yuan and colleagues reported that, among colorectal cancer patients, those in the highest quintile of dietary insulin load had a hazard ratio for cancer‑specific mortality of 2.82 (95% CI: 1.20–2.75; p = 0.006) compared with the lowest quintile. It is that simple: no dietary sugar, no cancer, it seems. But more precisely, hyperinsulinemia—driven by refined carbohydrates and sugar—is the soil in which cancer seeds germinate. Modifying the metabolic terrain: Dietary and lifestyle interventions Because hyperinsulinemia is reversible, it represents one of the most powerful opportunities for both cancer prevention and adjunctive treatment. 1. Dietary energy restriction Numerous studies show that dietary energy restriction—without malnutrition naturally lowers circulating glucose and insulin, reduces IGF‑1, and suppresses tumor growth across multiple types, including breast, brain, colon, pancreas, lung, and prostate. Importantly, calorie restriction targets the IGF‑1/PI3K/Akt/HIF‑1α signaling pathway, which underlies several cancer hallmarks. It also downregulates inflammation and tumor angiogenesis. 2. The ketogenic diet (KD) is a high‑fat, low‑carbohydrate, adequate‑protein regimen. A classic 4:1 KD delivers 90% of calories from fat, 8% from protein, and only 2% from carbohydrate. By drastically limiting glucose availability while providing ketone bodies—which normal cells can use efficiently but cancer cells cannot—the KD exploits the metabolic vulnerability of malignant cells. Variations include the medium‑chain triglyceride (MCT)‑based KD and the modified Atkins diet. MCTs are rapidly absorbed and converted to ketones, allowing for greater carbohydrate flexibility while maintaining therapeutic ketosis. 3. Intermittent fasting and autophagy Fasting stimulates autophagy—the cellular process of clearing damaged mitochondria, misfolded proteins, and senescent cells. Intermittent fasting (time‑restricted eating) is arguably the most effective non‑pharmacologic method to activate autophagy and improve insulin sensitivity. Recent evidence suggests that fasting can also enhance the response to chemotherapy across multiple tumor types (glioma, breast, colon, pancreatic, hepatocellular, lung) by:
Pharmacologic support: Berberine and metformin In addition to dietary strategies, specific pharmacologic agents can further reduce insulin signaling and activate anticancer pathways. Berberine, a plant alkaloid with a long history of use, exerts multiple anticancer effects:
A randomized, double‑blind study demonstrated that berberine 300mg twice daily significantly reduced the risk of recurrent colorectal adenoma following polypectomy. Preclinical and clinical data suggest potential benefit in breast, lung, gastric, liver, colorectal, ovarian, cervical, and prostate cancers. Hypoglycemia has not been reported with berberine, but blood glucose should be monitored when used with metformin. Metformin, an AMPK activator, lowers hepatic glucose output and insulin levels while inhibiting mTOR signaling—a key driver of cancer progression and autophagy suppression. In diabetic patients, those treated with insulin or insulin secretagogues have higher rates of solid cancers compared with those on metformin, highlighting metformin’s potential anticancer role. Metformin suppresses tumor initiation, growth, and spread and is recognized as an effective anticancer drug even for non-diabetics. Metformin has been demonstrated to reduce the risk of prostate cancer in men with diabetes. |
